SUMMARY
Several abstracts highlighted the efficacy of bispecific antibodies (BITEs) in the treatment of follicular lymphoma (FL), with interesting preliminary results in first line of treatment, both as monotherapy and combined with other agents. In the relapse/refractory (R/R) setting, robust and durable efficacy was shown for CAR-T particularly in the 3-year follow-up update of the ELARA trial. In first line CLL, an MRD-driven approach seems feasible and beneficial according to the results of the FLAIR trial. The update of the GLOW and the GAIA trials disclosed important information to identify the ideal molecular subgroup for each treatment combination. Finally, in the R/R setting, encouraging data from the use of non-covalent BTK inhibitor (ncBTKi) pirtobrutinib and CAR-T product lisocabtagene maraleucel (liso-cel) even in the poor prognosis group of patients exposed to both a covalent BTKi (cBTKi) and a BCL2 inhibitor (BCL2i).
(BELG J HEMATOL 2024;15(1):18–21)
